# Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy

> **NCT05111860** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shanghai Minimally Invasive Surgery Center** · enrollment: 20 (estimated)

## Conditions studied

- Neoadjuvant Treatment
- Rectal Cancer
- Bevacizumab
- Radiotherapy

## Interventions

- **DRUG:** Bevacizumab+mFOLFOX6

## Key facts

- **NCT ID:** NCT05111860
- **Lead sponsor:** Shanghai Minimally Invasive Surgery Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-01
- **Primary completion:** 2024-08-01
- **Final completion:** 2025-08-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05111860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05111860, "Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT05111860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*